Tuesday the European Commission and the European Investment Bank (EIB) Group announced an initiative to mobilise €10 billion in investment in 2026-27 into the biotech and life sciences sector. The project aims to give a significant boost to the EU’s competitiveness in biotechnology, by addressing the EU’s current investment gap and mobilising public-private investment into promising new health solutions.
The Commission has also adopted its proposal for a European Biotech Act, which is a key part of the push to boost European innovation and competitiveness, as highlighted in the Draghi report published last year.
Obviously, Medicon Valley Alliance is looking forward to assist the European Commission relaunching the EU as a leader in biotechnology by advancing R&D, fostering an ecosystem where biotech innovation can thrive and boosting the growth potential of biotech companies in the EU. As documented in the recently published analysis of the strongholds of the key European life science clusters mentioned in the Draghi report (and then we included The Golden Triangle in the UK as well), the cluster collaboration perspective is definitely part of the solution.